Cell-based high-throughput screen for small molecule inhibitors of Bax translocation

Area of Science:

• Biochemistry
• Cell Biology
• Pharmacology

Background:

• Aberrant programmed cell death (PCD) is implicated in numerous human diseases, including cancer, autoimmune disorders, and neurodegeneration.
• Modulating PCD signaling pathways is a key therapeutic strategy.
• Bcl-2 family proteins, particularly Bax, play a critical role in regulating the apoptotic pathway through mitochondrial translocation.

Purpose of the Study:

• To identify small molecules that inhibit Bax translocation to mitochondria, a critical step in PCD.
• To discover novel pharmacologic agents for modulating PCD.
• To investigate the role of cAMP in regulating Bax-mediated PCD.

Main Methods:

• A high-content, high-throughput screening of 6,246 Generally Recognized As Safe (GRAS) compounds was performed.
• Compounds were screened for their ability to inhibit Bax translocation following cisplatin-induced PCD.
• In vitro and in vivo assays were used to evaluate the efficacy of identified compounds in preventing apoptosis.

Main Results:

• 18 compounds were identified that significantly reduced Bax translocation.
• These compounds demonstrated protective effects by decreasing executioner caspase activity and improving mitochondrial function.
• The identified molecules effectively rescued cells from both in vitro and in vivo cisplatin-induced apoptosis.

Conclusions:

• A novel set of clinically relevant small molecules that inhibit PCD by targeting Bax translocation has been identified.
• These compounds represent potential therapeutic candidates for diseases associated with dysregulated PCD.
• The study highlights the regulatory role of cyclic adenosine monophosphate (cAMP) in Bax-mediated PCD.